ArticleInflammation2026
KANK4 Regulates CXCL16 Glycosylation Through TMEM260 to Modulate Microglial Activation in Sepsis-associated Encephalopathy.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Sepsis-associated encephalopathy (SAE) is a significant clinical condition leading to cognitive impairment, yet its molecular mechanisms remain to be fully elucidated. This study demonstrates that KANK4 expression is significantly downregulated in the hippocampus of SAE mice and in LPS-induced microglial cells, and this downregulation closely correlates with microglial overactivation and increased release of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α). Importantly, hippocampal overexpression of KANK4 not only markedly improved cognitive performance in SAE mice in the novel object recognition and Morris water maze (MWM) tests but also effectively alleviated hippocampal neuronal damage. Mechanistically, we confirmed that KANK4 directly binds to the 3'UTR of TMEM260 mRNA to enhance its stability, thereby inhibiting the O-mannosylation modification (with S117 as the key site) and protein expression of CXCL16. A series of functional experiments showed that TMEM260 overexpression significantly reduced CXCL16 levels and attenuated neuroinflammation, whereas CXCL16 overexpression completely reversed the neuroprotective effects of TMEM260. These findings reveal for the first time the crucial role of the KANK4-TMEM260-CXCL16 axis in regulating microglial activation, providing a new therapeutic target for SAE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.